Download - BD Presentation 080409
-
8/8/2019 BD Presentation 080409
1/17
-
8/8/2019 BD Presentation 080409
2/17
Corporate Presentation
-
8/8/2019 BD Presentation 080409
3/17
Introduction
Pharmaceutical and Consumer Health Company
Headquarters in UK
Listed on the London Stock Exchange
Rapid Growth since 1991 both organic and through productacquisition
Products bought from leading global pharmaceutical
companies Sales and marketing presence in Europe, USA & India
Operational base in UK, USA & India
-
8/8/2019 BD Presentation 080409
4/17
Introduction
Sales turnover 85 million year ended March 31, 2008
EBITDA of 17 million year ended March 31, 2008
Strong cash flow
More than 800 associates worldwide Wide range of products sold in more than 50 countries
Profitable, dividend paying company
-
8/8/2019 BD Presentation 080409
5/17
CONSUMER HEALTH
Group Structure
Consumer HealthPharmaceuticals
Operational, Medical,
Regulatory and SharedServices
Management Board
Europe India Intl Europe India Intl USA
Group Board
-
8/8/2019 BD Presentation 080409
6/17
Business Development PharmaceuticalsPresentation
-
8/8/2019 BD Presentation 080409
7/17
Business Development: Business Model
PharmaceuticalBusinessDivision
Speciality Brands
Mature BrandsGenerics
Strategy focus
-
8/8/2019 BD Presentation 080409
8/17
Our Pharmaceutical Business is split into 3 divisions:
Primary Care
Secondary Care
International
Geography
UK
Western Europe
International
Pharmaceutical Businesses
-
8/8/2019 BD Presentation 080409
9/17
Extensive distributor base and distribution channels
Covers more than 50 countries:
Europe (including the New EU members)
Far east (excluding Japan and China)
Australia, New Zealand and ASEAN countries(Singapore, Malaysia etc)
Africa ( South Africa and selected countries)Established worldwide network of manufacturing partners(including API) built over 15 years
Distribution
-
8/8/2019 BD Presentation 080409
10/17
Acquisition of niche tail end drugs mainly in Europeanmarkets to supplement the mature brand portfolio.
In-Licensing of niche specialty products to build brands.
Brand Leverage (reclassification)
Product Development (line extensions, New markets)
Diagnostics/Medical Devices
Alliances with multinationals to manage their non-coreproduct portfolio
Strategic Focus Business Development
-
8/8/2019 BD Presentation 080409
11/17
Previous Acquisitions
1992- 1997
Acquisitions from Glaxo
Chloromycetin Ophthalmic Ointment and Redidrops from
Parke Davis & Co Pitressin and Amsidine from Parke Davis.
Rheumox from Wyeth
Stelazine from Smithkline Beecham
Transphase from Transdermal University of SouthCalifornia
-
8/8/2019 BD Presentation 080409
12/17
Previous Acquisitions
1999
Kamillosan from Norgine
Lomotil from Monsanto
8 product licences ( including Fenbid and Stelazine) fromSmithKline
Nitrofurantoin from Procter & Gamble
2000
Trasidrex, Navispare, Navidrex from Novartis
Traxam from American Home Products
-
8/8/2019 BD Presentation 080409
13/17
Previous Acquisitions
2001
Antigen Group of companies worldwide.
Diamox range of products for Europe from Wyeth Division
of American Home Products
2002
Cytostatics and other tail end (10) products from Wyeth
-
8/8/2019 BD Presentation 080409
14/17
Products in late stages of development or technology
Medicines in disease areas which are not generallyfocused on by large multinational pharmaceuticals.
Palliative and critical care
Examples
Remodulin (treprostinil sodium) productAutodetect-Epidural device
In-Licensing
-
8/8/2019 BD Presentation 080409
15/17
Goldshield has a team with knowledge and experience inthe following areas:
AcquisitionsIntegration of acquisitions
Developing and implementing growth strategies
In LicensingMarketing products
International Distributor management
Knowledge Strengths
-
8/8/2019 BD Presentation 080409
16/17
Cardiology (Secondary Care)
Musculoskeletal and Joint diseases (Primary & Sec)
Pain/Anaesthesia (Secondary Care)
Therapeutic Focus
-
8/8/2019 BD Presentation 080409
17/17
Pharmaceutical Products
more than 400 products worldwide